Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025558 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025558: Completed Phase 1 study, sponsored by NYU Langone Health.
NCT00025558 is a Phase 1 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025558, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide, thiotepa, and carboplatin followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have brain cancer.
Interventions
- DRUG carboplatin
- DRUG temozolomide
- BIOLOGICAL filgrastim
- DRUG thiotepa
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Phase | Phase 1 |
What the finished NCT00025558 record still lists
NCT00025558 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00025558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025558 about?
NCT00025558 is a clinical study titled "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I tri...
What is the current status of trial NCT00025558?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-10.
What interventions are being tested in trial NCT00025558?
The interventions under investigation include: carboplatin (DRUG), temozolomide (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00025558?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia